The p53 signalling pathway plays a determinant role in oncogenesis and has recently been revealed as a master regulator in ADPKD progression via interaction with Wnt/beta‐catenin, c‐Jun N‐terminal kinase and MAPK signalling pathways.31, 32, 33, 34. The gene discussed is TP53; the disease is autosomal dominant polycystic kidney disease.